+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

CSF levels of receptor-active endorphins in schizophrenic patients: correlations with symptomatology and monoamine metabolites



CSF levels of receptor-active endorphins in schizophrenic patients: correlations with symptomatology and monoamine metabolites



Psychiatry Research 19(2): 93-100



Cerebrospinal fluid (CSF) levels of an opioid receptor-active, chromatographically separated endorphin fraction (Fraction I) were measured in 45 schizophrenic patients and 18 healthy volunteers. Significantly increased levels of Fraction I differentiated the patient group from controls, with no difference being found between newly admitted untreated and chronic previously neuroleptic-treated subjects. Fraction I levels did not correlate with age, weight, height, duration of illness, total time hospitalized, or age when symptoms first appeared. No differences were found between patients with or without a family history of schizophrenia. Fraction I levels were negatively correlated with "hallucinations" and "indecision" on the Comprehensive Psychopathological Rating Scale. Increased levels of Fraction I were associated with low levels of the dopamine metabolite homovanillic acid in drug-free schizophrenics. This relationship was not present after neuroleptic treatment or in healthy controls. No relationship was found between Fraction I and the serotonin metabolite 5-hydroxyindoleacetic acid. Neuroleptic treatment did not significantly change Fraction I levels; when only patients above the control range were considered, however, a significant decrease was observed. The data support our previous hypothesis of an increased opioid activity in schizophrenia and further indicate a concomitant dysfunction of brain endorphin and dopamine activity in schizophrenic patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039435826

Download citation: RISBibTeXText

PMID: 2431427


Related references

Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication. Zhonghua Shen Jing Jing Shen Ke Za Zhi 17(5): 273-277, 1984

Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history. Psychiatry Research 14(4): 265-273, 1985

Vasopressin levels in CSF of Alzheimer patients: correlations with monoamine metabolites and neuropsychological test performance. Psychoneuroendocrinology 14(1-2): 89-95, 1989

Low homovanillic acid and normal 5 hydroxyindoleacetic acid cerebrospinal fluid levels in drug free schizophrenic patients compared to healthy volunteers correlations to symptomatology and family history. Psychiatry Research 14(4): 265-274, 1985

CSF monoamine metabolites in schizophrenic patients. Acta Psychiatrica Scandinavica 66(5): 350-360, 1982

Correlations between standard auditory evoked potentials and symptomatology in a group of 50 schizophrenic patients. European Psychiatry 12(8): 387-394, 1997

CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide. Psychological Medicine 15(2): 335-340, 1985

Biogenic amine metabolites in plasma of drug-naive schizophrenic patients: Associations with symptomatology. Biological Psychiatry 32(3): 288-292, 1992

Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology 99(3): 322-327, 1989

P-4-47 Effects of clozapine on plasma monoamine metabolites in treatment-refractory schizophrenic patients. European Neuropsychopharmacology 5(3): 341-342, 1995

Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. European Neurology 18(1): 15-18, 1979

Neuropsychological test performance, brain morphological measures and CSF monoamine metabolites in schizophrenic patients. Acta Psychiatrica Scandinavica 74(3): 292-301, 1986

Decreased spinal fluid monoamine metabolites and norepinephrine in schizophrenic patients with brain atrophy. Beckmann, H And P Riederer (Ed ) Pathochemical Markers in Major Psychoses; Symposium, Vienna, Austria, July 1983 X+158p Springer-Verlag: New York, N Y , Usa; Berlin, West Germany Illus 88-95, 1985

Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers. Psychiatry Research 9(4): 301-308, 1983

Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochemistry International 56(6-7): 774-779, 2010